• About FESCA
  • Our Members
  • Scleroderma research
  • News & Events
  • Contact us
FESCA
Participate in the EUSHNeT survey!

Participate in the EUSHNeT survey!

February 18, 2013 | Projects, Survey

In an effort to improve non-pharmacological care for scleroderma patients, the EUSHNet project is attempting to evaluate the existing situation in health professional practice in scleroderma across European countries.

Recent news

  • Protect your skin
  • Joining forces in spreading awareness
  • COVID-19 catalogue
  • Edgar Stene Prize 2021
  • Focus on your wellbeing

News archive

  • January 2021
  • December 2020
  • November 2020
  • October 2020
  • September 2020
  • August 2020
  • June 2020
  • May 2020
  • April 2020
  • March 2020
  • January 2020
  • November 2019
  • June 2019
  • April 2019
  • February 2019
  • September 2018
  • June 2018
  • May 2018
  • April 2018
  • March 2018
  • December 2017
  • May 2017
  • November 2016
  • September 2016
  • July 2016
  • June 2016
  • May 2016
  • April 2016
  • March 2016
  • November 2015
  • October 2015
  • September 2015
  • July 2015
  • May 2015
  • March 2015
  • February 2015
  • November 2014
  • September 2014
  • July 2014
  • June 2014
  • May 2014
  • March 2014
  • February 2014
  • December 2013
  • June 2013
  • April 2013
  • March 2013
  • February 2013
  • June 2009

connect with us

 

Send us a message Send us a message

Like us on Facebook Like us on Facebook

Follow us on Twitter Follow us on Twitter

Follow us on Instagram Follow us on Instagram

Subscribe on Youtube Subscribe on Youtube

 

Legal disclaimer →
Data Protection Policy →

Donate today

 

Federation of European Scleroderma Associations aisbl

Rue du Pont à Rieu 13 i
7500 Saint Maur
Belgium

Federation of European Scleroderma Associations (FESCA )
© 2020 FESCA. Federation of European Scleroderma Associations is an International Non-Profit Association registered in Belgium with Registration No. FOJ 15454
We use cookies to give you the best experience on our website. By continuing to use the site we will assume you're happy with that.OKPrivacy policy